Dermatology · Fountain Valley, CA
NPI
1396741351
Since 2005
Specialty
Dermatology
Code 207N00000X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
17271 Brookhurst St
Fountain Valley, CA, 92708
Phone (714) 531-2966
Groups this clinician bills Medicare through
Medicare paid, 2024
$709K
14,943 services
Medicare patients, 2024
1,593
Average age 74
Drug cost, 2024
$7.2M
4,181 prescriptions
Company payments, 2025
$297K
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Tien Q Nguyen was code 99214 (office e&m - established), 2,569 times for 1,100 patients. In total Tien Q Nguyen billed 14,943 services in 83 codes, and Medicare paid $709K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 2,569 | 1,100 | $87.81 | $226K |
| 17003 Destruction Skin Lesion | Office | 1,735 | 201 | $5.22 | $9,064 |
| 99213 Office E&M - Established | Office | 1,393 | 706 | $64.72 | $90K |
| 17110 Destruction Skin Lesion | Office | 981 | 528 | $87.40 | $86K |
| 17111 Destruction Skin Lesion | Office | 624 | 267 | $101.87 | $64K |
| 17000 Destruction Skin Lesion | Office | 493 | 264 | $38.06 | $19K |
| 95044 Test - Miscellaneous | Office | 396 | 11 | $4.11 | $1,629 |
| 99204 Office E&M - New | Office | 351 | 351 | $103.59 | $36K |
| 17004 Destruction Skin Lesion | Office | 205 | 117 | $125.70 | $26K |
| 11102 Skin Biopsy | Office | 201 | 185 | $74.41 | $15K |
| 96920 Skin | Office | 157 | 30 | $124.08 | $19K |
| 99203 Office E&M - New | Office | 138 | 138 | $66.99 | $9,245 |
| 11103 Skin Biopsy | Office | 135 | 81 | $39.33 | $5,309 |
| 96372 Injection Administration | Office | 124 | 54 | $10.68 | $1,325 |
| 11900 Skin | Office | 120 | 41 | $39.04 | $4,685 |
By year: 2022 $300K for 5,891 services; 2023 $499K for 7,251 services; 2024 $709K for 14,943 services.
Medicare prescription drug claims, 2024
In 2024, the drug Tien Q Nguyen prescribed most often to Medicare patients was Mupirocin, with 608 prescriptions and refills. In total Tien Q Nguyen wrote 4,181 Medicare prescriptions that cost $7.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Mupirocin Generic | 608 | 612 | 474 | $3,794 |
| Triamcinolone Acetonide Generic | 537 | 596 | 284 | $4,591 |
| Cephalexin Generic | 453 | 453 | 394 | $2,055 |
| Dupixent Pen Dupilumab | 298 | 302 | 41 | $1.1M |
| Taltz Autoinjector Ixekizumab | 234 | 234 | 27 | $1.6M |
| Ketoconazole Generic | 228 | 243 | 86 | $4,396 |
| Doxycycline Hyclate Generic | 227 | 234 | 110 | $2,279 |
| Fluocinonide Generic | 170 | 181 | 82 | $5,841 |
| Hydrocortisone Generic | 163 | 163 | 104 | $717 |
| Methylprednisolone Generic | 120 | 120 | 98 | $801 |
| Cosentyx Sensoready (2 Pens) Secukinumab | 105 | 106 | 14 | $766K |
| Tacrolimus Generic | 103 | 103 | 38 | $14K |
| Otezla Apremilast | 85 | 85 | 18 | $397K |
| Clindamycin Phosphate Generic | 74 | 81 | 31 | $2,683 |
| Opzelura Ruxolitinib Phosphate | 64 | 64 | 17 | $126K |
Brand drugs: 1,241 claims; generic drugs: 2,940 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Tien Q Nguyen $297K ($297K in general payments such as food, travel and fees) from 24 companies. The largest payer was LEO Pharma Inc. with $40K.
| Company | Payments | Amount |
|---|---|---|
| LEO Pharma Inc. | 41 | $40K |
| Arcutis Biotherapeutics, Inc. ARQT | 36 | $35K |
| Genzyme Corporation SNY | 26 | $35K |
| Galderma Laboratories, L.P. GALD.SW | 44 | $33K |
| E.R. Squibb & Sons, L.L.C. BMY | 27 | $24K |
| Abbvie Inc. ABBV | 56 | $22K |
| UCB, Inc. UCB.BR | 32 | $22K |
| Janssen Biotech, Inc. JNJ | 31 | $17K |
| Incyte Corporation INCY | 28 | $17K |
| Amgen Inc. AMGN | 26 | $17K |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.